Andere talen Bristol-Myers Squibb Company Buenos Aires S.E.

Aandelen

BMY

ARDEUT112877

slotkoers Buenos Aires S.E. Andere beurzen 00:00:00 26-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
19.082 ^ARS	+3,13%		+8,59%	+15,95%

14:32	Purple Biotech zegt dat tussentijdse gegevens van onderzoek naar alvleesklierkanker veelbelovend zijn	MT
26/06	2seventy bio verkoopt Hemofilie A-kandidaat, genbewerkingstechnologie aan Novo Nordisk; aandelen stijgen na de uren	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	14:32
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	26/06
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	24/06
Bristol Myers : approbation accélérée en cancer colorectal	24/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	22/06
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	21/06
US FDA approves Bristol Myers' colorectal cancer therapy	21/06
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06
Bristol Myers : demande validée pour Opdivo sous-cutané	21/06
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab	21/06
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024	20/06
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil	19/06
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors	18/06
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	18/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Bristol-Myers CEO zegt dat het bedrijf in overgang is

09 januari 2024 om 19:06 uur